These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26700911)

  • 41. Gene expression profiling offers insights into the role of innate immune signaling in SSc.
    Johnson ME; Pioli PA; Whitfield ML
    Semin Immunopathol; 2015 Sep; 37(5):501-9. PubMed ID: 26223504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.
    Korman B
    Transl Res; 2019 Jul; 209():77-89. PubMed ID: 30876809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis.
    Fang D; Chen B; Lescoat A; Khanna D; Mu R
    Nat Rev Rheumatol; 2022 Dec; 18(12):683-693. PubMed ID: 36352098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intrauterine infection with parvovirus B19 and CMV: implications in early and late gestation fetal demise.
    Syridou G; Skevaki C; Kafetzis DA
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):651-61. PubMed ID: 16107203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Innate immunity and inflammation in systemic sclerosis.
    Lafyatis R; York M
    Curr Opin Rheumatol; 2009 Nov; 21(6):617-22. PubMed ID: 19633559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parvovirus B19 and systemic sclerosis.
    Ferri C; Azzi A; Magro CM
    Br J Dermatol; 2005 Apr; 152(4):819-20. PubMed ID: 15840133
    [No Abstract]   [Full Text] [Related]  

  • 47. Interstitial lung disease with cytomegalovirus and parvovirus B19 coinfection.
    Calabrese F; Giacometti C; Valente M; Loy M; Rea F
    Am J Clin Pathol; 2004 Oct; 122(4):614-5; author reply 615-6. PubMed ID: 15487462
    [No Abstract]   [Full Text] [Related]  

  • 48. T cells and cytokines in systemic sclerosis.
    Fuschiotti P
    Curr Opin Rheumatol; 2018 Nov; 30(6):594-599. PubMed ID: 30234723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human parvovirus B19 (B19V) infection in systemic sclerosis patients.
    Zakrzewska K; Corcioli F; Carlsen KM; Giuggioli D; Fanci R; Rinieri A; Ferri C; Azzi A
    Intervirology; 2009; 52(5):279-82. PubMed ID: 19672101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toll Like Receptors in systemic sclerosis: An emerging target.
    O'Reilly S
    Immunol Lett; 2018 Mar; 195():2-8. PubMed ID: 28888416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
    Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
    Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Parvovirus B19 and systemic sclerosis.
    Ferri C; Longombardo G; Azzi A; Zakrzewska K
    Clin Exp Rheumatol; 1999; 17(2):267-8. PubMed ID: 10342065
    [No Abstract]   [Full Text] [Related]  

  • 55. Pathogenic roles of B lymphocytes in systemic sclerosis.
    Yoshizaki A
    Immunol Lett; 2018 Mar; 195():76-82. PubMed ID: 29307688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human parvovirus B 19 and Epstein-Barr virus co-infection in a child with hereditary spherocytosis.
    Cefalo MG; Arlotta A; Maurizi P; Russo I; Sani I; Battista A; Mastrangelo S; Ruggiero A; Riccardi R
    Eur Rev Med Pharmacol Sci; 2012 Feb; 16(2):265-9. PubMed ID: 22428480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Innate Immunity in Systemic Sclerosis Fibrosis: Recent Advances.
    Laurent P; Sisirak V; Lazaro E; Richez C; Duffau P; Blanco P; Truchetet ME; Contin-Bordes C
    Front Immunol; 2018; 9():1702. PubMed ID: 30083163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.
    Drouet E; Chapuis-Cellier C; Bosshard S; Verniol C; Niveleau A; Touraine JL; Garnier JL
    Clin Exp Immunol; 1999 Dec; 118(3):465-72. PubMed ID: 10594569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting Costimulatory Pathways in Systemic Sclerosis.
    Boleto G; Allanore Y; Avouac J
    Front Immunol; 2018; 9():2998. PubMed ID: 30619351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.